Log in

Can-Fite Biopharma Stock Price, News & Analysis (NASDAQ:CANF)

$2.13
+0.01 (+0.47 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
$2.12
Now: $2.13
$2.17
50-Day Range
$1.92
MA: $2.31
$2.72
52-Week Range
$1.90
Now: $2.13
$25.95
Volume14,905 shs
Average Volume145,488 shs
Market Capitalization$2.84 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CANF
CUSIPN/A
CIKN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$2.84 million
Next Earnings Date11/29/2019 (Estimated)
OptionableOptionable

Receive CANF News and Ratings via Email

Sign-up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.


Can-Fite Biopharma (NASDAQ:CANF) Frequently Asked Questions

What is Can-Fite Biopharma's stock symbol?

Can-Fite Biopharma trades on the NASDAQ under the ticker symbol "CANF."

How were Can-Fite Biopharma's earnings last quarter?

Can-Fite Biopharma Ltd (NASDAQ:CANF) released its earnings results on Friday, August, 30th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by $0.40. The firm earned $0.39 million during the quarter. View Can-Fite Biopharma's Earnings History.

When is Can-Fite Biopharma's next earnings date?

Can-Fite Biopharma is scheduled to release their next quarterly earnings announcement on Friday, November 29th 2019. View Earnings Estimates for Can-Fite Biopharma.

What is the consensus analysts' recommendation for Can-Fite Biopharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Can-Fite Biopharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Can-Fite Biopharma.

Has Can-Fite Biopharma been receiving favorable news coverage?

Headlines about CANF stock have been trending negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Can-Fite Biopharma earned a news impact score of -2.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Can-Fite Biopharma.

Who are some of Can-Fite Biopharma's key competitors?

What other stocks do shareholders of Can-Fite Biopharma own?

Who are Can-Fite Biopharma's key executives?

Can-Fite Biopharma's management team includes the folowing people:
  • Prof. Pnina Fishman Ph.D., Scientific Founder, Chief Exec. Officer & Director (Age 70)
  • Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 54)
  • Dr. Ilan Cohn Ph.D., Co-Founder & Chairman (Age 64)
  • Dr. Michael H. Silverman M.D., F.A.C.P.,FACR, Medical Director
  • Dr. Vibeke Strand M.D., FACP, FACR (USA), Sr. Clinical Advisor

How do I buy shares of Can-Fite Biopharma?

Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Can-Fite Biopharma's stock price today?

One share of CANF stock can currently be purchased for approximately $2.13.

How big of a company is Can-Fite Biopharma?

Can-Fite Biopharma has a market capitalization of $2.84 million. View Additional Information About Can-Fite Biopharma.

What is Can-Fite Biopharma's official website?

The official website for Can-Fite Biopharma is http://www.canfite.co.il/.


MarketBeat Community Rating for Can-Fite Biopharma (NASDAQ CANF)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  175
MarketBeat's community ratings are surveys of what our community members think about Can-Fite Biopharma and other stocks. Vote "Outperform" if you believe CANF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CANF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel